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N O T  P E E R - R E V I E W E D  
An Overview on Drug Evolution and Trials on  
Pandemic COVID-19 Infection 
Munendra Mohan Varshney*, Avantika Sharma  
Raj Kumar Goel Institute of Technology (Pharmacy), Delhi Meerut Road Ghaziabad, India 
A B S T R A C T  
The disease caused by severe acute respiratory syndrome (SARS-CoV2) is highly pathogenic and 
communicable infection, progressed in Wuhan city of China and then around the world. The 
Genomic investigations shows that phylogenetically SARS-CoV2 resembles the other SARS-like bat 
viruses, therefore bats were also considered as the possible potential reservoir for SARS-CoV2. 
COVID-19 pandemic has presented considerable challenges to public health care system at global 
scale. Novel COVID-19 virus is member of corona Viridae family. Drug evolution and alternative 
therapy has come in the focus prominently in the treatment of COVID-19 infection. Although, 
clinical trials, also be in faster rate in all over the world. A number of drugs which were previously 
used against SARS-CoV-2 infection such as Remdesevir, Lopinavir, Ritonavir, Interferon beta-1b and 
Ribavirin, but they are being tested in randomised trials and show less prominent effects. In the 
review we summarized the latest research progress nationally and internationally on treatment and 
clinical trials of COVID-19 pandemics.  
Keywords: COVID-19, Plasma Therapy, Clinical Trial. 
1. Introduction 
World pandemic threat COVID-19 seriousness is crucial to the human life and for reducing distortion of 
livelihood.  International Committee on Taxonomy of Viruses (ICTV) labelled SARS-CoV-2 (SARS- 
Severe Acute Response Syndrome) virus induced corona virus disease. COVID-19 was outbreak from 
Wuhan, China from 2020 January1. Similar kind of outbreak was happened previously with different 
pathogens named SARS-CoV in 2003 and Middle East Respiratory Syndrome Coronavirus-MERS-CoV 
(Since 2015, centred on Arabian Peninsula)2. However, SARS-CoV-2 virus promoting respiratory 
problems and ease of spreading (through air droplets) will make severe life threats than the other, hence 
COVID-19 is belonging to Corona Viridae family and size is 65-125 nm diameters approximately. After 
outbreak from china, according to the worldometer.info, on 26th July 2020, approximately 16,205,467 
peoples have been affected with COVID-19, 648,476 peoples death occurs and 9,914,060 peoples 
recovered, still it continuous on. An overall good sign has been mortality rate (6%) worldwide. The 
affected patients are increasing in the rate of multiplication; thus, world governments should make 
consensus to eradicate the COVID-19 as much earlier, which will be helpful to save the poor population 
globally3.WHO is gathering daily international multilingual scientific findings and knowledge on COVID-
19 4.  
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2.Drug Evolution 
2.1 Hydroxychloroquine: Chloroquine has been used worldwide for more than 70 years. However, it is 
also a part of WHO model of essential list. The efficacy and safety of Hydroxychloroquine for the 
treatment of SARS-CoV-2 (new virus causing COVID-19) pneumonia, still remain not known5. More 
than a billion Indians currently stand at the precipice of a massive increase in cases of Coronavirus disease 
2019 (COVID-19). India had shown a staggered course of severe acute respiratory syndrome Coronavirus 
(SARS-CoV-2) transmissions, with 1397 cases diagnosed between Jan 31, and April 1 of 2020. However, 
there has been a recent surge in cases, with numbers rising to 1,387,481 as of 26th July 2020 6. The Indian 
Council of Medical Research (ICMR), under the Ministry of Health and Family Welfare, recommended 
chemoprophylaxis with Hydroxychloroquine (400 mg twice on day 1, then 400 mg once a week 
thereafter) for asymptomatic healthcare workers treating patients with suspected or confirmed COVID-
19, and for asymptomatic household contacts of confirmed cases caused by COVID-19 7. 
 
 2.2 Remdesivir Remdesivir (Antiviral) is a Prodrug of a nucleotide analogue that is intracellular 
metabolized to an analogue of Adenosine Triphosphate that inhibits viral RNA polymerases. By June 
2020, several potential post infection therapies including Remdesevir, Favipiravir and Topinavir used in 
international solidarity trial. Remdesivir has broad spectrum activity against members of several virus 
families, including Filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and Middle East 
respiratory syndrome coronavirus [MERSCoV]) and exhibited prophylactic and therapeutic efficacy in 
nonclinical models of these coronaviruses 8.  
2.3 Other Promising Drugs used against COVID-19 infection 
Currently, there are no FDA approved treatments for COVID-19, although lots of drugs (Table 1) are 
being tested against COVID-19 infection 9. 
 
Table 1: List of promising drugs against COVID-19 infection 
List of drugs Category 
Baricitinib Janus kinas inhibitor 
Bemcentinib AXL kinase inhibitor 
Bevacizumab VEGF inhibitor 
Colchicin Anti-inflammatory 
Eidd-2801 Oral antiviral 
Favipiravir Antiviral 
Fingolimod Against multiple sclerosis 
Azithromycin Antibiotics 
Lvermectin Anti-Parasitic 
Leronlimab CCR5 antagonist 
Lopinavir and Ritonavir Anti-HIV 
Methylprednisolone Glucocorticoids 
Remdesivir and Umifenovir Antiviral 
Sarilumab Il-6 receptor antagonist 
Tocilizumab Il-6 receptor antagonist 
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2.4 Developing COVID-19 Vaccines at Pandemic Speed 
Vaccine development is a lengthy, expensive process, Attrition is high, and it typically takes multiple 
candidates volunteers and many years to produce a licensed vaccine for human beings.  Because of the 
cost and high failure rates, developers typically follow a linear sequence of steps, with multiple pauses for 
data analysis or manufacture in process checks. To developing a vaccine quickly requires a new pandemic 
paradigm with a fast start and many steps executed in parallel before confirming a successful outcome of 
another step, hence resulting in elevated financial risk. For platforms with respective experience in 
humans, phase 1 clinical trials may be able to proceed in parallel steps with testing in animal models 10, 11. 
According to WHO guidelines, Participation in Solidarity Trial in March 2020 provides simplified 
procedures to enable even overloaded hospitals to participate, with no paperwork required. As of April 21 
2020, over 100 countries are advised to working together to find effective therapeutics as soon as 
possible, via the trial. The greater the number of participating countries, the faster results will be 
generated 12. Conservative estimated of time needed to prove a safe and effective vaccine is about early 
2021. As per survey on 25th July 2020 by MarketWatch,com,  Some leading pharmaceutical industries 
which are working on coronavirus treatments 13. However, seven Indian pharmaceutical companies like 
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotech, Indian Immunologicals, Mynvax and 
Biological E, are in race to develop COVID-19 vaccine. Bharat biotech has received approval to conduct 
phase 1 and 2 clinical trials for vaccine candidate (Covaxin) that as on July 2020, started human clinical 
trials. Leading vaccine major serum institute of India and Astra Zeneca oxford undergoing phase 3 clinical 
trials and will started human trials in India in Aug 2020 14. 
Table.2 List of Pharmaceutical Companies Working on Coronavirus Treatment 
Companies Type Stage name 
Amagen And Adaptive 
Biotechnologies 
Antibody Treatment Preclinical AdCOVID 
BioNTech and Pfizer m RNA Vaccine Phase 1/2 BNT162 Program 
Cytodyn Treatment Phase 2 and Phase 2b/3 
Clinical Trial 
Leronlimab 
Gilead sciences Treatment Emergency and 
Authorization 
Remdesivir 
Heat Biological Vaccine Preclinical No name yet 
Inovio Pharmaceuticals DNA based vaccine Phase-1 Clinical Trial INO-4800 
Johnson and johnson Vaccine Phase-1 Clinical Trial  No name yet 
Moderna RNA-based Vaccine Phase-1 Clinical Trial m RNA-1273 
Novavax Vaccine Phase-1 Clinical Trial NVX-CoV2373 
Regeneron Prevention and 
Treatment 
Phase-1 Clinical Trial REGN-COV2 
Regeneron 
Pharmaceuticals 
Treatment Phase 2/3 Clinical Trials Kevzara 
Roche Treatment Phase 3 Clinical Trial Actemra 
Sanofi vaccine Preclinical No name yet 
Takeda pharmaceuticals Antibody Treatment Preclinical TAK-888 
Vaxart Vaccine Preclinical No name yet 
Vir Biotechnology Vaccine Preclinical VIR-2703 
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2.5 Plasma Therapy 
According to the therapeutic studies, Convalescent plasma or immunoglobulin, have been used to 
improve the survival rate of patients with SARS whose condition continued to deteriorate despite 
treatment with corticosteroids (Methyl Prednisolone). Moreover, several studies showed a shorter hospital 
stay and lower mortality in patients treated with convalescent plasma than those who were not treated 
with convalescent plasma 15. In 2014, the use of convalescent plasma collected from recovered patients 
from Ebola virus disease, was recommended by World Health Organization (WHO) as an empirical 
treatment during outbreaks. A protocol for the convalescent plasma used in the treatment of Middle East 
respiratory syndrome Coronavirus 16. The following steps were taken Donors for Convalescent Plasma 
Transfusion, Plasma Preparation Procedure and Quality Control, Serology Test and Real-Time RT-PCR, 
Detection of SARS-CoV-2 and Other Pathogens, Treatment ( with antibiotics, antifungal, glucocorticoids, 
oxygen support), Data Collection 17. Using data from March 31 (2020), which according to some data of  
JHU indicates 330 infections in India, it was founded that, among 11 quarantine scenarios, with 50% 
effective quarantine,  1,387,481  citizens in India would become infected, while 10% effective quarantine 
would result in 521 million infections. These grim numbers suggest that solutions other than social 
distancing are urgently needed to combat the epidemic and to minimize the loss of life 18. 
 
2.6 Anti-cytokine therapeutics 
Baricitinib (Antiviral agent) was used in April 2020, for first clinical trial and show anti-cytokine effects. 
However, Ruxolinitib and Acalabrutinib were used as IL-1 and IL-6 inhibitors. Tocilizumab is IL-6, Janus 
kinase and TNF inhibitor which inhibit the inflammation and decrease entry of SARS-CoV-2, shown 
remarkable effects in anti-cytokine therapeutics 19. 
 
3. Randomized Clinical Trials during Disease Outbreaks 
Conducting trials of novel interventions during infectious disease emergencies, such as the ongoing 
COVID-19 pandemic, is increasingly recognized as important for determining the efficacy of potential 
vaccines and therapies. Clinical trials to evaluate investigational interventions are being implemented as 
part of the broader efforts to control the spread of an infectious disease and to improve patient 
outcomes. In such circumstances, however, it can be challenging to acquire the necessary evidence about 
the effects of the interventions to inform future patient care and public health planning, in part because 
of the unpredictable size, geographic location, and duration of outbreaks 20. A number of clinical trials 
and study have the important role to overcome infectious disease. Controlled PREVAIL (Partnership for 
Research on Ebola Virus in Liberia) II trial for the triple monoclonal antibody cocktail ZMapp, which 
helped in investigation of a large Ebola outbreak in the Democratic Republic of Congo (DRC) in 2018, 
investigators used ZMapp rather than the standard of- care treatment as the control against which to 
compare other Ebola therapeutics in the randomized Another trial used, PALM trial (Investigational 
Therapeutics for the Treatment of People with Ebola Virus Disease). There is an obvious need to balance 
the importance of publishing the results of all completed clinical trials against the potential adverse 
consequences. Thus, new approaches to clinical trials are welcome to enable reliable evaluations of 
vaccines and treatments for outbreak pathogens 21-23. 
 
5. Drug design and laboratory testing 
New chemical entities (NCEs) are the compounds that emerge from the process of drug discovery to a 
specific vaccine or antiviral therapeutic agents which having promising effects for activity against a 
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biological target related to COVID-19 infection. However, in addition drug development must establish 
the related physicochemical parameters which are directly related to stability, solubility and optimization 
of NCE 24. 
6. Conclusion 
In this review we obtained the relevant information from articles, online recourses and focused much on 
therapies drug development and vaccines development currently being used against COVID-19. As the 
knowledge on SARS-CoV-2/COVID-19 pandemic is still evolving. As per WHO guideline avoid the 
contact with sick person and also avoid the market or public place as per possible. There are no anti 
corona virus vaccine to prevent or treatment but some supporting therapy work. We summarized the 
current trends related to decreases the effect of SARS-CoV-2, drugs evolutions and trials struggle to find 
out the promising results. World’s leading Pharmaceutical Companies are developing new vaccines to 
decrease the infections caused by COVID-19. New drugs and therapies in progressive stage globally and 
trying to decrease the effect of corona virus infections and COVID-19 outbreaks. However new drug 
entities (NCE) also in progressive stage.  
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